Jiangsu Hengrui Medicine
600276.SS
#449
Rank
A$77.48 B
Marketcap
A$11.68
Share price
-1.97%
Change (1 day)
13.93%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): A$0.19

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.18. In 2024 the company made an earnings per share (EPS) of A$0.19 an increase over its 2023 EPS that were of A$0.14.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.19-0.45%
2024A$0.1942.43%
2023A$0.148.77%
2022A$0.12-20.62%
2021A$0.16-26.59%
2020A$0.2127.24%
2019A$0.1728.41%
2018A$0.1320.04%
2017A$0.1131.21%
2016A$0.0830411.46%
2015A$0.0745136.27%
2014A$0.0546819.77%
2013A$0.0456518.05%
2012A$0.0386723.9%
2011A$0.0312126.9%
2010A$0.0245912.37%
2009A$0.0218956.6%
2008A$0.013989.18%
2007A$0.01280114.48%
2006A$0.00596964.83%
2005A$0.00362135.55%
2004A$0.00267229.73%
2003A$0.00205919.86%
2002A$0.001718-2.71%
2001A$0.0017661.02%
2000A$0.001748